Allarity Therapeutics, Inc. Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax
Allarity Therapeutics, Inc. (ALLR) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax of $267.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax · last filed 2026-08-14
- Allarity Therapeutics, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2026-06-30 was $267.00K, a 85.41% decline year-over-year.
- Allarity Therapeutics, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2026-03-31 was $58.00K, a 78.99% decline year-over-year.
- Allarity Therapeutics, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-09-30 was -$158.00K.
- Allarity Therapeutics, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-06-30 was $1.83M.
- Allarity Therapeutics, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2025 was $667.00K, a 1070.18% increase from fiscal 2024.
- Allarity Therapeutics, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2024 was $57.00K, a 81.61% decline from fiscal 2023.
- Allarity Therapeutics, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2023 was $310.00K.
- Allarity Therapeutics, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2022 was -$121.00K.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 3 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 3 month as first filed | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 6 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 9 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 12 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $267.00K 10-Q · filed 2026-08-14 | $325.00K derived: sum of 2 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | $58.00K 10-Q · filed 2026-08-14 | |||||
| 2025-12-31 | $667.00K 10-K · filed 2026-03-30 | |||||
| 2025-09-30 | -$158.00K 10-Q · filed 2025-11-14 | $1.67M derived: sum of 2 quarters · filed 2026-08-14 | $1.95M derived: sum of 3 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $1.83M 10-Q · filed 2026-08-14 | $1.83M 10-Q · filed 2025-08-15 | $2.11M derived: sum of 2 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $276.00K 10-Q · filed 2026-08-14 | -$276.00K 10-Q · filed 2025-05-09 | ||||
| 2024-12-31 | $57.00K 10-K · filed 2026-03-30 | -$57.00K 10-K · filed 2025-03-31 | ||||
| 2024-09-30 | -$163.00K 10-Q · filed 2025-11-14 | $163.00K 10-Q · filed 2024-11-14 | -$307.00K derived: sum of 2 quarters · filed 2025-11-14 | -$282.00K derived: sum of 3 quarters · filed 2025-11-14 | -$9.00K derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | -$144.00K 10-Q · filed 2025-11-14 | -$119.00K derived: sum of 2 quarters · filed 2025-11-14 | $154.00K derived: sum of 3 quarters · filed 2025-11-14 | $62.00K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $25.00K 10-Q · filed 2025-11-14 | $298.00K derived: sum of 2 quarters · filed 2025-11-14 | $206.00K derived: sum of 3 quarters · filed 2025-11-14 | $177.00K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2023-12-31 | $273.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $181.00K derived: sum of 2 quarters · filed 2024-11-14 | $152.00K derived: sum of 3 quarters · filed 2024-11-14 | $310.00K 10-K · filed 2024-03-08 | ||
| 2023-09-30 | -$92.00K 10-Q · filed 2024-11-14 | $92.00K 10-Q · filed 2023-11-14 | -$121.00K derived: sum of 2 quarters · filed 2024-11-14 | $37.00K 10-Q · filed 2023-11-14 | -$1.43M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$29.00K 10-Q · filed 2024-11-14 | $29.00K 10-Q · filed 2023-08-14 | -$55.00K 10-Q · filed 2023-08-14 | -$1.34M derived: sum of 3 quarters · filed 2024-11-14 | -$694.00K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-03-31 | $84.00K 10-Q · filed 2024-11-14 | -$1.31M derived: sum of 2 quarters · filed 2024-11-14 | -$665.00K derived: sum of 3 quarters · filed 2024-11-14 | -$251.00K derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2022-12-31 | -$1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$749.00K derived: sum of 2 quarters · filed 2024-03-08 | -$335.00K derived: sum of 3 quarters · filed 2024-03-08 | -$121.00K 10-K · filed 2024-03-08 | ||
| 2022-09-30 | $643.00K 10-Q · filed 2023-11-14 | $1.06M derived: sum of 2 quarters · filed 2023-11-14 | $1.27M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | $414.00K 10-Q · filed 2023-08-14 | -$414.00K 10-Q · filed 2022-10-07 | $628.00K 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$214.00K 10-Q · filed 2022-10-07 | |||||
| 2021-12-31 | -$1.97M 10-K · filed 2023-03-13 | |||||
| 2021-03-31 | -$459.00K 10-Q · filed 2022-10-07 | |||||
| 2020-12-31 | $2.51M 10-K · filed 2022-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |